News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
Researchers affiliated with the Pancreatic Cancer Action Network found that treatment based on patient molecular profiles improved progression-free survival.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The company posted Q1 revenues of $7.5 million, up from $5.3 million in Q1 2017 and above the consensus Wall Street estimate of $7.1 million.
Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.
In a recent study, Mills and his colleagues determined the platform has suitable throughput, quantitative performance, and reproducibility for the clinic.